Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009.SANTA MONICA MONICA Cardiology A WHO initiative–Multinational Monitoring of Trends & Determinants of Cardiovascular Disease–which evaluated the effects of various factors on mortality in Pts MIs , Calif. and LAS VEGAS, Aug. 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI CBAI The Community Bankers Association of IllinoisCBAI Contract Bridge Association of Ireland (UK) ) , one of the largest umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. stem cell preservation companies (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that work has begun at its new, 17,000 square foot facility in Las Vegas for conversion into a state-of-the-art laboratory for the storage of stem cells and for research and development. "Our target for having a cord blood processing lab in operation, a testing lab, and a cryogenic storage area is the fourth quarter of 2009. This will complete Phase One of the construction. Currently architectural plans are completed and needed demolition of parts of the interior building is underway," said Matthew Schissler, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and founder of Cord Blood America. "Phase Two will involve building out of the largest cryogenic facilities in the country, as well as a research laboratory, additional processing labs and a clean room," Mr. Schissler said. "Completion is expected in 2010." Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas. The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as stem cells from the peripheral blood stream and adipose adipose /ad·i·pose/ (ad´i-pos) 1. fatty. 2. the fat present in the cells of adipose tissue. ad·i·pose adj. Of, relating to, or composed of animal fat; fatty. tissues, and for research and product development. Dr. Geoffrey John O'Neill, author or co-author of more than 75 publications about stem cells, and former Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida, will serve as Laboratory Director. Brian Pockett, with more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development, including serving as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S., is Vice President of Laboratory Operations. About Cord Blood America Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/. Forward-Looking Statements Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments Medical researchers believe that stem cell treatments have the potential to change the face of human disease and alleviate suffering. A number of stem cell treatments already exist, although most are still experimental and/or costly, with the notable exception of bone marrow , and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement. CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365, pknopick@eandecommunications.com, for Cord Blood America Web Site: http://www.cordblood-america.com/ |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion